Light Street Capital Management’s Myriad Genetics MYGN Stock Holding History

Light Street Capital Management’s Portfolio MYGN Stock Details MYGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q2	–	Sell	-220,000	Closed	-$7.52M	–	48
2014 Q1	$7.52M	Buy	+220,000	New	+$6.82M	1.38%	26

Other funds holding MYGN

Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

BTS

BB&T Securities Richmond, Virginia $10.9B AUM 5.31% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SCM

Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

IAM

Iridian Asset Management Westport, Connecticut $291M AUM 49.45% 1-Year Est. Return

Tiger Global Management New York $22.8B AUM 30.07% 1-Year Est. Return

Light Street Capital Management's MYGN Position: Q2 2014 in Review

Light Street Capital Management sold out of Myriad Genetics (MYGN) in Q2 2014, closing a stake of 220,000 shares — an estimated $7.52M sold.

Light Street Capital Management first reported a position in MYGN in Q1 2014 and held it in 1 quarter. The position peaked at $7.52M in Q1 2014. 284 funds tracked by Wall St. Rank hold MYGN as of Q2 2014.

Light Street Capital Management reported no remaining Myriad Genetics position as of Q2 2014 after selling out during the quarter.
Light Street Capital Management sold 220,000 Myriad Genetics shares in Q2 2014, an estimated $7.52M.
Light Street Capital Management first reported a position in Myriad Genetics in Q1 2014 and held it in 1 quarter.
Light Street Capital Management's Myriad Genetics position peaked at $7.52M in Q1 2014.
284 funds tracked by Wall St. Rank held Myriad Genetics as of Q2 2014.

Based on Light Street Capital Management's 13F filing for Q2 2014, filed 14 Aug 2014.